Nicotinamide mononucleotide ameliorates DNFB-induced atopic dermatitis-like symptoms in mice by blocking activation of ROS-mediated JAK2/STAT5 signaling pathway.

Gao JF, Tang L, Luo F, Zhang YY, Chen L, Ding H, Meng ZD

International immunopharmacology6 May 2022Cited by 16 (Europe PMC)

PMID35533554DOI10.1016/j.intimp.2022.108812PepBankPUB-35533554

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with DNFB-induced dermatitis, NMN alleviated AD-like symptoms.
In plain wordsIn mice, NMN reduced dermatitis-like symptoms.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseAD-like symptoms
Study
mousen: not reported in source
DNFB-induced dermatitis in KM mice
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated · topical · two weeksAs given in this study (mouse).
Source sentences
Summary
NMN exhibited potent anti-atopic activities, shown by alleviated AD-like symptoms, inhibited the increased expression of inflammatory cytokines and restored proteins and mRNA level of skin barrier genes.
1 context sentence(design, population, supporting numbers)
Summary · context
KM mice were treated with DNFB to induce AD-like lesion and typical applied with NMN for two weeks.
Report a problemFND-3553355401
02AnimalAnimal study (in vivo)Mechanism
In mice with DNFB-induced dermatitis, NMN inhibited increased inflammatory cytokine expression.
In plain wordsIn mice, NMN reduced increased inflammatory cytokine expression in dermatitis.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseInflammatory cytokine expression
Study
mousen: not reported in source
DNFB-induced dermatitis in KM mice
Outcome group
Inflammation markers · Skin and wound
Studied dose
Dose not stated · topical · two weeksAs given in this study (mouse).
Source sentences
Summary
NMN exhibited potent anti-atopic activities, shown by alleviated AD-like symptoms, inhibited the increased expression of inflammatory cytokines and restored proteins and mRNA level of skin barrier genes.
1 context sentence(design, population, supporting numbers)
Summary · context
KM mice were treated with DNFB to induce AD-like lesion and typical applied with NMN for two weeks.
Report a problemFND-3553355402
03AnimalAnimal study (in vivo)Mechanism
In mice with DNFB-induced dermatitis, NMN restored skin barrier protein levels.
In plain wordsIn mice, NMN restored skin barrier protein levels in dermatitis.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
MixedSkin barrier protein levels
Study
mousen: not reported in source
DNFB-induced dermatitis in KM mice
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated · topical · two weeksAs given in this study (mouse).
Source sentences
Summary
NMN exhibited potent anti-atopic activities, shown by alleviated AD-like symptoms, inhibited the increased expression of inflammatory cytokines and restored proteins and mRNA level of skin barrier genes.
1 context sentence(design, population, supporting numbers)
Summary · context
KM mice were treated with DNFB to induce AD-like lesion and typical applied with NMN for two weeks.
Report a problemFND-3553355403
04AnimalAnimal study (in vivo)Mechanism
In mice with DNFB-induced dermatitis, NMN restored skin barrier gene mRNA levels.
In plain wordsIn mice, NMN restored skin barrier gene mRNA levels in dermatitis.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
MixedSkin barrier gene mRNA
Study
mousen: not reported in source
DNFB-induced dermatitis in KM mice
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated · topical · two weeksAs given in this study (mouse).
Source sentences
Summary
NMN exhibited potent anti-atopic activities, shown by alleviated AD-like symptoms, inhibited the increased expression of inflammatory cytokines and restored proteins and mRNA level of skin barrier genes.
1 context sentence(design, population, supporting numbers)
Summary · context
KM mice were treated with DNFB to induce AD-like lesion and typical applied with NMN for two weeks.
Report a problemFND-3553355404
05LabIn vitro (cells)Mechanism
In stimulated NHEK cells, NMN inhibited elevated inflammatory chemokines.
In plain wordsIn cells, NMN reduced inflammatory chemokines after inflammatory stimulation.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseInflammatory chemokines
Study
n: not reported in source
TNF-α/IFN-γ-stimulated NHEK cells
Outcome group
Inflammation markers · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
In addition, NMN inhibited TNF-α/IFN-γ-stimulated elevation of inflammatory chemokines, which was associated with blocking the activation of ROS-mediated JAK2/STAT5 pathway.
1 context sentence(design, population, supporting numbers)
Summary · context
NHEK cells were stimulated by TNF-α/IFN-γ after pre-treatment with NMN, then ROS levels, inflammatory factors and JAK2/STAT5 signaling pathway were detected.
Report a problemFND-3553355405
06LabIn vitro (cells)Mechanism
In stimulated NHEK cells, NMN inhibition of chemokines was associated with blocked ROS-mediated JAK2/STAT5 activation.
In plain wordsIn cells, NMN reduced chemokines in association with blocked ROS-mediated JAK2/STAT5 activation.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseROS-mediated JAK2/STAT5 activation
Study
n: not reported in source
TNF-α/IFN-γ-stimulated NHEK cells
Outcome group
Receptor activity and mechanism · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
In addition, NMN inhibited TNF-α/IFN-γ-stimulated elevation of inflammatory chemokines, which was associated with blocking the activation of ROS-mediated JAK2/STAT5 pathway.
1 context sentence(design, population, supporting numbers)
Summary · context
NHEK cells were stimulated by TNF-α/IFN-γ after pre-treatment with NMN, then ROS levels, inflammatory factors and JAK2/STAT5 signaling pathway were detected.
Report a problemFND-3553355406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.